Navigation Links
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
Date:6/24/2009

LEUVEN, Belgium, June 25 /PRNewswire-FirstCall/ --

- Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that its lead product microplasmin, which is in Phase III trials for the treatment of vitreomacular adhesion, is progressing according to schedule. All protocol-specified, interim masked analyses by the independent Data Monitoring Committee (DMC) have been completed. Recruitment is on track and the DMC, having found no safety concerns, has unanimously recommended proceeding without protocol modification.

Microplasmin's Phase III program is referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program. This program involves two clinical trials, taking place in the United States (TG-MV-006 trial) and Europe and the United States (TG-MV-007 trial). The indication for both of the Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion.

Focal vitreomacular adhesion is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye. These adhesions can cause vessel and retinal distortion which results in deterioration in the patient's vision. Moreover, vitreomacular adhesion is thought to play a key role in numerous back of the eye conditions such as macular hole formation, and some forms of macular edema. Vitreomacular adhesion is also potentially associated with a much poorer prognosis in certain major eye indications, including diabetic retinopathy and Age-related Macular Degeneration (AMD).

Both of the Phase III studies are mult
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PRNewswire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ...forminimallydisruptivesurgicaltreatmentsforthespin...day,November30,2009,at5:30p.m.ET/2:30p.m.PT.Thecon...ursementfortheCompany,sproductsandwillincludecomme...session.Thedial-innumbersare1-877-407-4018fordomes...
(Date:11/25/2009)...andSYDNEY,Nov.25/PRNewswire-FirstCall/--HeartWareI...nnovatorandprovideroflessinvasive,miniaturizedcirc...entofadvancedheartfailure,todayannouncedthatitissc...PiperJaffrayHealthCareConferenceat8:00amESTonWedne...ewYorkPalaceHotel,December1-2. ,, Alivewebcasto...
(Date:11/24/2009)....24/PRNewswire-FirstCall/--QuestDiagnosticsIncorpo...ostictesting,informationandservices,announcedthati...thcareConferenceinNewYorkCity.Thepresentationissch...Time. ,, Duringtheconference,thecompanywillreaf...,operatingincometoexceed18%ofrevenues,anddilutedea...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2New chemistry techniques improve hybrid scanner performance 48911 1New chemistry techniques improve hybrid scanner performance 48911 2Pregnant women at high risk of complications from H1N1 influenza 48908 1American Dental Association The Forsyth Institute Collaborate to Pilot Evidence Based Dentistry Training Course 48905 1American Dental Association The Forsyth Institute Collaborate to Pilot Evidence Based Dentistry Training Course 48905 2American Dental Association The Forsyth Institute Collaborate to Pilot Evidence Based Dentistry Training Course 48905 3
...ation Demonstrate Advantages Ov...nd, October 1 Critical,Pharmaceuticals, the Notti..., today announced that the successful completion o...ation of the synthetic human growth,hormone (hGH) ...,concentrations were achieved over an extended per...
...re-FirstCall/ --,Pharmaceutical company Pharmaxis ...rketing application for the mucus clearing agent, ...Goods Administration (TGA) division of,the Austral...horized to,market Bronchitol in Australia for the ...based on a multicentre Phase 3 clinical trial,invo...
Other Medicine Technology:Critical Pharmaceuticals Enter Sustained Release hGH Arena 2ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia 2
(Date:11/25/2009)...ewswire-FirstCall/-- OnyxPharmaceuticals,Inc.(Nas...investoreventsinDecember: ,, ASHBriefing ,..., Principalinvestigatorswilldiscussdatapresentatio...multiplemyeloma,asfeaturedatthe51stAmericanSociety...leans,LA.Theteleconferencewillbeginat9:00a.m.CT/10...
(Date:11/25/2009)...-USNewswire/--TheBlackAIDSInstituterecentlyheldBoa...pfor2010. ,, ThenewBoardMembersareahighlydivers...inance,governmenthealthprograms,editorial,andbusin...eofpersonalbackgroundsincludingbothheterosexualand...drepresentingmultipleagegroups. ,, (Photo: http...
(Date:11/25/2009)... out of a collaboration between UCLA engineers and...arly 10 million Americans who suffer from peripher...ng of the arteries, peripheral arterial disease, o...rrowed arteries reduce blood flow to the limbs. Th...disease, heart attack and stroke, and its progress...
(Date:11/25/2009)...thers to overlook needed care, study finds , ...ther,s depression can worsen her child,s asthma, U...tudy of 262 black mothers and their children found...ymptoms had more frequent asthma symptoms, while c...had less frequent asthma symptoms. , The Johns ...
(Date:11/25/2009)...he4thStraightYear ,, WASHINGTON,Nov.25/PRNews...ia(LCA-GA)issuedthe 4thAnnualReportCardonLungCance...nstthislethaldiseaseinthestateofGeorgia.LCA-GAisac...anizationdedicatedexclusivelytopatientsupportandad..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
...ors qualified in Electropathy, an alternative syst...in support of their demand for jobs in state-run ...gh the use of electricity. The doctors, w...nt to meet Chief Minister Ghulam Nabi Azad with th...
...archers at the University of Virginia Health Syste...hey hope will restore hearing, into diseased tissu...ngs scientists closer to curing genetic or acquire...ser, an assistant professor of otolaryngology, tar...
...al warming is speeding up ocean waves, a new study...ctoria in British Columbia, has found. Geo..., these so-called planetary waves should speed up....und that gigantic ocean waves, spanning hundreds o...
...ins have found new evidence that supports the link...ions related to smallpox vaccination . Imm...llpox vaccine, is sometimes found to cause reactio... University, St. Louis University, and The Emmes C...
...non-governmental organisation Friends Africa said ... dollars (15 million euros) to combat AIDS, tuber...kesman said on Wednesday. "We are raising ...ent. Aig-Imoukhuede, who is also the manag...
...oys go obese in the US, so does their sense of sh...necomastia. So they undergo the surgeons knife rea...of Plastic Surgeons, nearly 14,000 boys age 13 to...increase of 21 percent over the previous year for ...
Other Medicine News:Health News:New Evidence Links Smallpox Vaccination Side Effects to Genetic Factors 2Health News:Breast Reduction Surgery Among Boys Rising in US 2Health News:Breast Reduction Surgery Among Boys Rising in US 3
...lse to stimulate deep and otherwise inaccessible n...lators. Based upon equipment first developed by th...phasic stimulator for accurate cortical hemispheri...for Central Motor Conduction Studies, Brain Mappin...
...rgical approach to glaucoma management that employ...n. The ciliary body (which produces aqueous humour...osterior segment, through the endoscope in real ti...dentified utilizing endoscopy. This allows discret...
...rgical approach to glaucoma management that employ...n. The ciliary body (which produces aqueous humour...osterior segment, through the endoscope in real ti...dentified utilizing endoscopy. This allows discret...
...rgical approach to glaucoma management that employ...n. The ciliary body (which produces aqueous humour...osterior segment, through the endoscope in real ti...dentified utilizing endoscopy. This allows discret...
Medicine Products: